On September 7, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that new data on RXDX-105 – a VEGFR-sparing, potent RET inhibitor – will be presented in a late-breaking proffered paper session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2017 Congress in Madrid, Spain on Sunday, September 10 at 5:15 p.m. Central European time (Press release, Ignyta, SEP 7, 2017, View Source [SID1234520408]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A conference call and live webcast will be held on September 11, 2017, at 5:00 a.m. Pacific time (8:00 a.m. Eastern time) to discuss highlights of the data presented and to provide a pipeline review, including lead product candidate entrectinib—an orally bioavailable, CNS-active tyrosine kinase inhibitor focused on targeting tumors that harbor NTRK fusions or ROS1 fusions, currently being studied in a registration-enabling Phase 2 clinical trial known as STARTRK-2.

To participate in the conference call, please dial (800) 930-1344 (U.S.) or (719) 457-2642 (international) and provide Conference ID 6430774. To access the live webcast, go to View Source." target="_blank" title="View Source." rel="nofollow">View Source

A replay of the presentation will be available shortly after the conclusion of the live call in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.